(Reuters) - Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New ...

The future of the weight loss market might not revolve around GLP-1 drugs.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Bagsværd, Denmark, 14 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with ...

In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...

The US regulator has said that compounders can continue to trade in tirzepatide products while it undertakes a review to ...

Pharmaceutical company Lundbeck will acquire Nasdaq-listed Longboard Pharmaceutical in a $2.6 billion deal, the two companies ...

India’s powerful copycat pharmaceutical industry is set to roll out generic weight-loss drugs in the UK within weeks, with one leading producer forecasting a “huge price war t ...

The once-weekly injectable joins one-shot haemophilia B gene therapy Beqvez (fidanacogene elaparvovec) in Pfizer’s portfolio, ...

As prices for Ozempic have risen in recent months, many people may be seeking cheaper alternatives for managing diabetes or ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

Combined with Schenker, the company will have a workforce of 147,000 and revenue of 293 billion Danish crowns ($43.52 billion) based on 2023 results, more than Danish drug company Novo Nordisk. DSV ...